Moderna skyrockets 11% after receiving additional $472 million of funding, starting Phase 3 trial of COVID-19 vaccine
Published
**
· *Moderna on Sunday announced it received a commitment of up to $472 million in additional funding from its contract with the Biomedical Advanced Research and Development Authority. *
· *The company on Monday announced that the Phase 3 trial for its COVID-19 vaccine had started dosing participants. *
· *Shares of...